Nectin Therapeutics, established by Integra Holdings in 2017, is dedicated to the development of next generation immuno-oncology antibodies. The company's antibodies are based on the discoveries and inventions of Prof. Ofer Mandelboim from the Hebrew University and Prof. Stipan Jonjic from the University of Rijeka. Integra Holdings & Yissum are the key shareholders.
Dr. Guy Cinamon VP R&D
Dr. Pini Tsukerman CSO
Mr. Anas Atieh Lab manager
Dr. Alon Vitenshtein Senior Scientist
Dr. Akram Obiedat Senior Scientist